The results indicated that the expression of SOCS3 mRNA was upregulated in lymphoma, esophageal cancer, and glioma compared with normal tissues, while the expression of SOCS3 mRNA was downregulated in bladder cancer, lung cancer, leukemia, and sarcoma compared with the respective normal controls (Figure 3A). This evidence concerns the gene SOCS3 and lung carcinoma.